Ozempic for Depression Patients: Evidence, Eligibility

Ozempic is not FDA approved for depression. It is approved for type 2 diabetes, heart risk and kidney disease in type 2 diabetes. Some doctors prescribe it when one of those uses also applies. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.

Active ingredient: semaglutide
How it is taken: weekly injection
Approved for: Type 2 diabetes, heart risk and kidney disease in type 2 diabetes
Best result (STEP 1): 14.9% weight loss

Ozempic in brief

How long the drug remains in the body

Its half-life is about 1 week. After 7 d, half is gone. At five half-lives (35 d), about 3% remains.

Main trial weight loss

In SUSTAIN 1, people with type 2 diabetes lost 4.7 kg over 30 weeks, against 1.2 kg on placebo.

Cost over time

The maker's price page lists monthly list price and self-pay offers in US dollars.

Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.

Who qualifies?

Who can qualify for Ozempic?
Who sets the rule	Who qualifies
FDA label	When used with diet and exercise, it lowers blood sugar in adults with type 2 diabetes.
FDA label	This medicine lowers the risk of death related to the heart, a heart attack, or a stroke in adults with type 2 diabetes and heart disease.
FDA label	When an adult has type 2 diabetes and chronic kidney disease, this medicine lowers the risk of kidney failure, worsening kidney disease, and death linked to the heart.
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	you must first try a diet and activity program for 6 months

Reference material: DailyMed FDA label and aetna.com.

Trial results for depression

Depression alone was not the condition studied in any of these trials. Every participant was an adult with obesity or overweight, and none had diabetes.

Studies that use semaglutide, the same ingredient
Trial	Medicine	Who took part	Length	People	Main result	Comparison
STEP 1	Wegovy	Adults with obesity or overweight, without diabetes	68 weeks	1,961	14.9% weight loss	2.4% on placebo
OASIS 4	Wegovy	Adults with obesity or overweight, without diabetes	64 weeks	307	13.6% weight loss	2.4% on placebo

Trial source: STEP 1 (FDA label (DailyMed)).

What is different for depression?

Ozempic label details for depression
What changes	What the label says
Severe Gastrointestinal Adverse Reactions	Common side effects in the stomach and gut can be severe. Not recommended for people with severe gastroparesis.

These details come from the FDA labels: FDA label (DailyMed).

Warnings taken from the label: FDA label (DailyMed).

Coverage for depression

A GLP-1 used only for weight loss is not covered by Medicare Part D.

When Medicaid covers weight-loss GLP-1s, it usually requires prior authorization.

Sources: humana.com, KFF.

Alternatives for depression

GLP-1 medicines and depression
Medicine	For people with depression	How it is taken	Trial result
Ozempic	Not a listed use	weekly injection	Not listed
Wegovy	Not a listed use	weekly injection or daily tablet	14.9% weight loss
Rybelsus	Not a listed use	daily tablet	Not listed
Mounjaro	Not a listed use	weekly injection	Not listed
Zepbound	Not a listed use	weekly injection	20.9% weight loss
Foundayo	Not a listed use	daily tablet	11.1% weight loss
Trulicity	Not a listed use	weekly injection	Not listed
Saxenda	Not a listed use	daily injection	7.4% weight loss
Victoza	Not a listed use	daily injection	Not listed
Byetta	Not a listed use	twice-daily injection	Not listed